Getting ahead of neuropathic pain
by Bruce Sylvester – Researchers at Boston Children’s Hospital and the Massachusetts Institute of Technology report the discovery a potential method to delay the onset of neuropathic pain.
by Bruce Sylvester – Researchers at Boston Children’s Hospital and the Massachusetts Institute of Technology report the discovery a potential method to delay the onset of neuropathic pain.
Laser-based measurements are proving to be a promising method for the assessment of osteoporosis. The team led by Professor Jussi Timonen has developed an ultrasound technique that… read more.
Deep Brain Stimulation Surgery Deep Brain Stimulation (DBS), lesion surgery, and other new and innovative technologies are currently being used at UF to treat the symptoms of Parkinson’s… read more.
by Bruce Sylvester – Researchers at Boston Children’s Hospital and the Massachusetts Institute of Technology report the discovery a potential method to delay the onset of neuropathic pain.
Ramon L. Rodriguez, M.D., Associate Professor, University of Florida Center for Movement Disorders & Neurorestoration.
Ramon L. Rodriguez, M.D., Associate Professor, University of Florida Center for Movement Disorders & Neurorestoration.
Dr Michael Okun, M.D., Professor, University of Florida Center for Movement Disorders & Neurorestoration.
Kelly D. Foote, M.D., Associate Professor, University of Florida Center for Movement Disorders & Neurorestoration. Dr. Foote was attending the Movement Disorder Society’s 16th International Congress of Parkinson’s… read more.
Erin M. Dunbar, M.D., Assistant Professor and Co-Director, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Department of Neurosurgery, University of Florida.
by Marybeth Burke – Initial combination chemotherapy with bendamustine and rituximab more than doubled progression-free survival to nearly 6 years compared with standard R-CHOP therapy among patients with… read more.
by Marybeth Burke – Adding bevacizumab to chemotherapy halves the risk of the disease getting worse in platinum resistant patients with ovarian cancer,
by Marybeth Burke – Crizotinib demonstrated significant anti-tumour activity in patients with advanced non-small cell lung cancer (NSCLC) harbouring ROS1 rearrangements,
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.